Diego F. Calvisi

Diego F. Calvisi

Franz Josef Strauß Allee 11
Regensburg, BY 93053, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 220 publications

Targeting Fatty Acids in Liver Cancer: Molecular Insights and Drug Approaches.

Targeting Fatty Acids in Liver Cancer: Molecular Insights and Drug Approaches.

Journal: Biomolecules

Published: January 02, 2026

The Novel HSF1 Inhibitor NXP800 Exhibits Robust Antitumor Activity in Hepatocellular Carcinoma.

The Novel HSF1 Inhibitor NXP800 Exhibits Robust Antitumor Activity in Hepatocellular Carcinoma.

Journal: International journal of molecular sciences

Published: December 17, 2025

SIRT6-GLUL axis: rewiring nitrogen metabolism in intrahepatic cholangiocarcinoma.

SIRT6-GLUL axis: rewiring nitrogen metabolism in intrahepatic cholangiocarcinoma.

Journal: Gut

Published: November 11, 2025

Overexpression of ONECUT1 suppresses hepatoblastoma progression via modulating tumor cell growth and tumor microenvironment.

Overexpression of ONECUT1 suppresses hepatoblastoma progression via modulating tumor cell growth and tumor microenvironment.

Journal: Cell & bioscience

Published: November 11, 2025

Cholangiocarcinoma 2026: status quo, unmet needs and priorities.

Cholangiocarcinoma 2026: status quo, unmet needs and priorities.

Journal: Nature reviews. Gastroenterology & hepatology

Published: October 31, 2025

Uncoupling Metastasis and Epithelial-to-Mesenchymal Transition in sgP19/kRAS-Driven Spontaneous Metastatic Liver Tumor Model.

Uncoupling Metastasis and Epithelial-to-Mesenchymal Transition in sgP19/kRAS-Driven Spontaneous Metastatic Liver Tumor Model.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: July 29, 2025

The DNA Minor Groove Binders Trabectedin and Lurbinectedin Are Potent Antitumor Agents in Human Intrahepatic Cholangiocarcinoma.

The DNA Minor Groove Binders Trabectedin and Lurbinectedin Are Potent Antitumor Agents in Human Intrahepatic Cholangiocarcinoma.

Journal: International journal of molecular sciences

Published: July 18, 2025

Targeting mTORC2-dependent AKT/FOXO1/RNF125 signaling exploits a therapeutic vulnerability in c-MET-activated and β-catenin-mutated hepatocellular carcinoma.

Targeting mTORC2-dependent AKT/FOXO1/RNF125 signaling exploits a therapeutic vulnerability in c-MET-activated and β-catenin-mutated hepatocellular carcinoma.

Journal: Hepatology (Baltimore, Md.)

Published: June 14, 2025

Supplementary biomarker testing in molecular tumor boards increases actionable therapy recommendations: a prospective real-world study of 658 patients.

Supplementary biomarker testing in molecular tumor boards increases actionable therapy recommendations: a prospective real-world study of 658 patients.

Journal: BMC medicine

Published: May 02, 2025

Inhibition of GSK3 and TSC2 Mediates the Oncogenic Activity of AKT in Hepatocellular Carcinoma.

Inhibition of GSK3 and TSC2 Mediates the Oncogenic Activity of AKT in Hepatocellular Carcinoma.

Journal: Cancer research

Published: April 12, 2025

NEDD8-specific protease 1 deficiency as a novel driver of hepatoblastoma development through dysregulation of the CAND1-NEDD8 pathway.

NEDD8-specific protease 1 deficiency as a novel driver of hepatoblastoma development through dysregulation of the CAND1-NEDD8 pathway.

Journal: Hepatology (Baltimore, Md.)

Published: April 03, 2025

Distinct molecular pathways regulated by activated AKT and YAP signaling during intrahepatic cholangiocarcinoma progression.

Distinct molecular pathways regulated by activated AKT and YAP signaling during intrahepatic cholangiocarcinoma progression.

Journal: Journal of hepatology

Published: March 13, 2025

Showing 1-12 of 220

Last Updated: 09/26/2026